BAUSCH HEALTH COMPANIES INC.

ISIN: CA0717341071 WKN: 071734107

Overview

2024/05/24 22:00:01					
Price 6.36 USD					
Difference	0	0.16% (0.01)			

General attributes				
ISIN	CA0717341071			
Symbol	BHC			
Exchange	NYSE			
Currency	USD			
Sector	Other			
Security type	Stock			
Market cap (m)	2,151 EUR			
Benchmark	S&P/TSX 60 INDEX			

Market data	
Bid (Bid size)	6.30 USD (100)
Ask (Ask size)	6.46 USD (2,000)
Open	6.35 USD
High	6.45 USD
Low	6.315 USD
Close (prev. day)	6.35 USD
VWAP	6.37495 USD
Volume (pcs)	2,031,448
Trading volume	12,950,221.05
Number of trades	11,198
Last size	-

Futures and Options	
Related Futures	15
Related Options	-

PDF Downloads	
Company report: BAUSCH HEALTH COMPANIES INC.	



Information about previous performance does not guarantee future performance. **Source:** FactSet

Recent research

on sector			
Date		Headline	Download
2024/04/26	60. 126 621 120	Global Equity Ratings	
2024/04/03	55. Let 27. 176	Global Equity Ratings	
2024/03/13	80 Jan 80 TS	Global Equity Ratings	
2024/02/22	55. Let 27. 176	Global Equity Ratings	
2024/02/14	80 Jan 80 TS	Global Equity Ratings	



Details

2024/05/24 22:00:01					
Price					
6.36 USD					
Difference	0	0.16% (0.01)			

General attributes				
ISIN	CA0717341071			
Symbol	ВНС			
Exchange	NYSE			
Currency	USD			
Sector	Other			
Security type	Stock			
Market cap (m)	2,151 EUR			
Benchmark	S&P/TSX 60 INDEX			

Market data	
Bid (Bid size)	6.30 USD (100)
Ask (Ask size)	6.46 USD (2,000)
Open	6.35 USD
High	6.45 USD
Low	6.315 USD
Close (prev. day)	6.35 USD
VWAP	6.37495 USD
Volume (pcs)	2,031,448
Trading volume	12,950,221.05
Number of trades	11,198
Last size	-

Performance and Risk							
	6m 1Y 3Y						
Perf (%)	-6.94%	-22.78%	-76.81%				
Perf (abs.)	-0.65	-2.57	-28.85				
Beta	1.35	1.05	1.75				
Volatility	39.35	41.02	72.26				



Information about previous performance does not guarantee future performance. $\textbf{Source:} \ \ \textbf{FactSet}$

Price data	
Ø price 5 days Ø volume 5 days (pcs.)	6.43 USD (2,544,025)
Ø price 30 days Ø volume 30 days (pcs.)	7.72 USD (3,104,861)
Ø price 100 days Ø volume 100 days (pcs.)	8.54 USD (2,906,428)
Ø price 250 days Ø volume 250 days (pcs.)	8.15 USD (2,719,682)
YTD High date	11.46 USD (2024/04/03)
YTD Low date	6.26 USD (2024/05/23)
52 Weeks High date	11.46 USD (2024/04/03)
52 Weeks Low date	6.26 USD (2024/05/23)

All listings for BAUSCH HEALTH COMPANIES INC.					
Exchange 🖨	Date	Time	Price	Trading volume (mio.)	Number of trades
Tradegate	2024/05/ 27	15:44	5.844 EUR	0.00	1
Toronto Stock Exchange	2024/05/ 27	18:40	8.51 CAD	0.65	376
Stuttgart	2024/05/ 27	17:42	5.732 EUR	0.00	5
SIX Swiss Exchange	2019/06/ 28	17:35	24.11 CHF	0.00	1
NYSE	2024/05/	22:00	6.36 USD	12.95	11,198



	24				
Munich	2024/05/ 27	08:03	5.942 EUR	0.00	1
Frankfurt	2024/05/ 27	09:15	5.779 EUR	0.00	1
Duesseldorf	2024/05/ 27	08:10	5.777 EUR	0.00	1
Berlin	2024/05/ 27	08:03	5.783 EUR	0.00	1



Company profile

Company Logo

BAUSCH Health

Contact Details

BAUSCH HEALTH COS. INC.

_ _

2150 St. Elzéar Boulevard West - H7L 4A8 Laval

Telefon: +1-514-744-6792

Fax: + E-mail: -

PDF Downloads

Company report: BAUSCH HEALTH COMPANIES INC.

đ.

Company Profile

Bausch Health Cos., Inc. engages in the development, manufacture and market of a range of branded, generic and branded generic pharmaceuticals, medical devices and over-the-counter products. It operates through the following segments: Salix, International, Solta Medical, Diversified Products, and Bausch + Lomb. The Salix segment consists of sales in the U.S. of GI products. Sales of the Xifaxan product line. The International segment comprises of sales, except for sales of Bausch + Lomb products and Solta aesthetic medical devices, outside the U.S and Puerto Rico of branded pharmaceutical products, branded generic pharmaceutical and OTC products. The Solta Medical segment refers to global sales of Solta Medical aesthetic medical devices. The Diversified Products segment covers sales in the U.S. of pharmaceutical products in the areas of neurology and certain other therapeutic classes, generic products, ortho dermatologic, and dentistry products. The Bausch + Lomb segment are global sales of Bausch + Lomb vision care, surgical and ophthalmic pharmaceuticals products. The company was founded on March 29, 1994, and is headquartered in Laval, Canada.

Members of Management Board			
Thomas Appio	Chairman of Managing Board		
Tage Ramakrishna	Member of Executive Committee		
Cees Heiman	Member of Executive Committee		
Fernando Zarate	Member of Executive Committee		
Graham Jackson	Member of Executive Committee		
Jeff Hartness	Member of Executive Committee		
Kathleen Fitzpatrick	Member of Executive Committee		
Mirza Dautbegovic	Member of Executive Committee		
Seana Carson	Member of Executive Committee		

Member of Executive

Committee

Tom Vadaketh

Board of directors			
John Paulson	Chairman of Supervisory Board		
Amy Wechsler	Member of Supervisory Board		
Richard Mulligan	Member of Supervisory Board		
Brett Icahn	Member of Supervisory Board		
Christian Garcia	Member of Supervisory Board		
Frank Lee	Member of Supervisory Board		
Robert Power	Member of Supervisory Board		
Sarah Kavanagh	Member of Supervisory Board		
Steven Miller	Member of Supervisory Board		

